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The Ne w E n g l a nd Jo u r n a l o f Me d ic i ne

limited to patients with tumors 5 cm or less in diameter,
long-term survival approaches 75 percent at four years,
whereas transplantation in those with tumors larger than
5 cm has been associated with less than 30 percent survival.2,3 These data led to the exclusion of patients with larger
tumors from the waiting list for cadaveric organs. We suggest that if the supply of cadaveric organs were to exceed the
current demand, patients with the worst outcomes would be
considered candidates. Can we now refuse to offer these patients transplantation when a healthy living donor provides
the graft?

patients. In our article, we refer to the need to balance the
short-term and long-term risks to the donor with the potential benefits to the recipient. The proposal offered by Shaked
and Lucey demonstrates the need for the transplantation
community to specify what outcomes in a recipient are acceptable before a living donor is subjected to surgical risk.
It also raises the question of whether individual programs
can be required to comply with standards established by the
surgical transplantation community through professional
self-regulation.
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The authors reply:
To the Editor: We agree with most of the views of Miller
and Delmonico, including their conclusions that the “transplantation community . . . does indeed monitor itself ” and
that it shows “concern for the well-being of living donors.”1,2
In our article, we never question this commitment. We
also agree that the surgical model of innovation based on
professional self-regulation rather than administrative regulation has proved to be an extremely effective way to advance the field of surgery to benefit patients.
Our disagreement with Miller and Delmonico focuses
on whether the professional regulatory model involving conferences, colloquiums, and position papers will prove adequate for dealing with the transplantation of liver grafts
from adult living donors and for protecting potential donors. We believe that the best way to optimize the use of
this innovative technology is to define clearly the experimental protocol, standardize the operation, ensure the “field
strength” of the surgical team, and record and share all
data on outcomes (including program-specific data) with
the professional community and with patients. If the professional community can accomplish these tasks quickly —
and thus far they have not — there may not be a need for
formal regulatory control.
Shaked and Lucey highlight an unresolved issue with regard to recipients. Since the four-year survival among patients who have hepatocellular carcinomas larger than 5 cm
and undergo transplantation is so poor,3 this group has been
excluded from the waiting list for cadaveric organs. Shaked
and Lucey suggest that living donors be subjected to complications and possibly death to provide grafts to recipients
with hepatocellular carcinomas, even though the transplantation community has declined to use cadaveric grafts in such
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3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the
treatment of small hepatocellular carcinomas in patients with cirrhosis.
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MHC Class I Molecules and Progression
to AIDS
To the Editor: Gao et al. (May 31 issue)1 report the identification of specific HLA-B*35-Px subtypes as responsible
for the association between HLA-B*35 and rapid progression to AIDS, and they stress the importance of homozygosity for HLA-B*35 as a predictor of even more rapid progression. Their extensive analysis confirms the known protective
effect of the HLA-B*27 and B*57 subtypes against progression to AIDS, at least in whites.2
Unlike Gao and colleagues, we think that there is an important influence of numerous major-histocompatibilitycomplex (MHC) gene products. The A1,B8,DR3 haplotype,
for instance, has repeatedly been shown to be associated
with fast progression to human immunodeficiency virus
(HIV) disease and rapid loss of CD4 T cells,3,4 and several
other HLA haplotypes can predict disease progression.2
Caution should be exercised before early, aggressive antiretroviral therapy is recommended for HLA-B*35–positive
patients. We have been following an HIV-infected woman
without symptoms since her seroconversion in 1991 (she is
now 37 years old). She has never received antiretroviral therapy and still has a high CD4 cell count (606 per cubic millimeter, 36.6 percent of total lymphocytes) and CD4:CD8
ratio (0.91), despite being homozygous for HLA-B*35. Perhaps the presence of HLA A2,A26 alleles in her haplotype
counteracts the effects of HLA-B*35, since A2 is common
in frequently exposed HIV-seronegative persons5 and A26
may confer resistance to the progression of HIV disease.2
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The authors reply:
To the Editor: To date, over 50 papers have been published that attempt to associate HLA haplotypes with the
rate of progression to AIDS. Because of low statistical power and small samples, the results of many cannot be considered rigorously validated. Among the strongest associations are the influence of HLA class I homozygosity and
the codominant influence of HLA-B*35. The goal of our
recent report was to demonstrate that the previously reported effect of B*351 could be connected directly to the peptide-binding specificity of certain HLA-B*35 subtypes. We
are, of course, aware of several other genetic factors that
mitigate progression to AIDS, including the genes encoding CC chemokine receptors 5 and 2, interleukin-10, and
stromal-cell–derived factor 1 as well as other HLA alleles,
and we described them in our cohorts.1,2 These factors may
counteract each other, which could be the case for the
HLA-B*35–homozygous woman described by Cainelli et al.
This patient’s AIDS-free survival for 10 years is remarkable. In our experience with six patients homozygous for
HLA-B*35 in five cohorts, five progressed to an AIDSdefining condition in less than 6 years and the other one
in less than 10 years.
We agree that multiple genetic and viral influences should
be considered when a therapeutic regimen for an HIV-

TABLE 1. CLINICAL CHARACTERISTICS
SEX

AGE

URINARY PROTEIN

62
60
43
71
55
74

Male
Female
Mean ±SD*

61
31
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Spironolactone in Addition to ACE Inhibition
to Reduce Proteinuria in Patients with Chronic
Renal Disease
To the Editor: Angiotensin-converting–enzyme (ACE)
inhibitors have been shown to reduce proteinuria and slow
the progression of renal disease.1 Although to date angiotensin II has been the focus of attention as the primary mediator of the renin–angiotensin–aldosterone system, several
studies have raised the possibility that aldosterone itself has
a role in mediating progressive renal disease.2,3 Pitt et al.4
showed that blockade of aldosterone receptors by spironolactone significantly reduced the risk of morbidity and death
among patients with heart failure who were already receiving
ACE inhibitors. The authors hypothesized that the benefits
were not due to the hemodynamic effects of spironolactone but, instead, may have been due to an adverse effect
of aldosterone on myocardial and vascular smooth-muscle
cells. We tested the hypothesis that spironolactone may act
along with ACE inhibitors in the kidney to reduce proteinuria.

BEFORE AND AFTER

CREATININE CLEARANCE

TREATMENT

AFTER

BEFORE

AFTER

BEFORE

AFTER

TREATMENT

TREATMENT

TREATMENT

TREATMENT

TREATMENT

TREATMENT

g/day

2.87
8.90
2.83
3.00
2.21
6.17

ml/sec

0.94
3.30
2.94
1.80
0.86
2.02

1.30
0.58
2.50
0.62
2.40
1.24

WITH

SYSTOLIC PRESSURE

BEFORE

yr

Male
Male
Female
Male
Male
Male

AND

infected patient is chosen. We believe that B*35-Px is one
of the more influential factors.

SPIRONOLACTONE

IN

DIASTOLIC PRESSURE
BEFORE

EIGHT PATIENTS.
DIAGNOSIS

AFTER

TREATMENT TREATMENT

mm/Hg

0.66
0.59
2.02
0.45
3.90
1.30

1.17
0.36
1.71
1.51
3.30
1.75
0.48
0.53
3.81±2.50 1.75±1.02 1.35±0.80 1.37±1.17

120
120
120
200
170
120
140
120
138.8±30.4

120
110
110
170
130
130

80
80
90
100
90
90

70
70
70
90
80
80

160
90
70
115
90
80
130.6±22.7 88.8±6.4 76.3±7.4

Type 2 diabetes
Type 2 diabetes
Systemic lupus erythematosus
Type 2 diabetes
Type 2 diabetes
Focal sclerosis with segmental hyalinosis
Type 2 diabetes
Vasculitis

*P<0.02 for the comparison between pretreatment and post-treatment urinary protein, by the paired t-test. There were no other significant differences
between pretreatment and post-treatment values.
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